Panelists discuss how airway clearance devices and techniques, including chest physical therapy, active cycle breathing, ...

Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as ...

The drug is manufactured by the US firm Insmed and made possible after 15 years of research by scientists from the University ...

Good afternoon, and thank you for joining the Electromed earnings call. Earlier today, Electromed, Inc. released financial results for the third fiscal quarter of 2025, the quarter ended March 31, ...

Gross profit rose to $12.2 million, representing 78.0% of net revenues. Selling, general, and administrative expenses were $9.8 million, a 17.2% increase. Operating income was $2.1 million, net income ...

The world’s first potential therapy for an increasingly common, chronic lung condition has been identified following a trial ...

British scientists have developed a world-first treatment for an incurable condition that contributed to the Pope’s death.

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...

Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024- -NDA ...

Insmed Incorporated , a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported ...